Latest Press Releases Jan 10 2025 Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore Read More Dec 23 2024 Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13 Read More Dec 20 2024 Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis Read More Dec 20 2024 Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non-F508del TRIKAFTA-Responsive Variants Read More Dec 19 2024 Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy Read More Dec 08 2024 Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the American Society of Hematology (ASH) Annual Meeting and Exposition and Provides Program Update Read More Load More Recent Media Library Items View All Date - Any -2021202220232024 Tags Chief Executive Officer and PresidentDownload LibraryEmployee working at Vertex Manufacturing Center (VMC), Boston, MAEmployee working at Vertex Manufacturing Center, Boston, MAEntrance of The Jeffrey Leiden Center for Cell and Genetic Therapies, Boston, MAExecutive ChairmanExecutive Vice President and Chief Financial OfficerExecutive Vice President and Chief Legal OfficerExecutive Vice President and Chief of Cell and Genetic TherapiesExecutive Vice President and Chief Operating OfficerExecutive Vice President and Chief Patient OfficerExecutive Vice President and Chief Regulatory and Quality OfficerExecutive Vice President and Chief Scientific OfficerExecutive Vice President and Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical OfficerExecutive Vice President, Global Research and Chief Scientific OfficerExterior of Vertex headquarters in Boston, MAExterior of Vertex headquarters in Paddington, UKExterior of Vertex research site in Oxford, UKExterior of Vertex research site in San Diego, CAImagesInterior of Vertex headquarters in Boston, MALiving with beta thalassemiaLiving with sickle cell diseaseLiving with transfusion-dependent beta thalassemiaLiving with transfusion-dependent thalassemiaMother to three daughters living with sickle cell diseaseResearcher in Vertex Oxford labResearcher in Vertex San Diego labResearchers in Vertex Boston labResearchers in Vertex Oxford labResearchers in Vertex San Diego lab Nia Tatsis, Ph.D. Executive Vice President and Chief Regulatory and Quality Officer Download Date - Any -2021202220232024 Tags Chief Executive Officer and PresidentDownload LibraryEmployee working at Vertex Manufacturing Center (VMC), Boston, MAEmployee working at Vertex Manufacturing Center, Boston, MAEntrance of The Jeffrey Leiden Center for Cell and Genetic Therapies, Boston, MAExecutive ChairmanExecutive Vice President and Chief Financial OfficerExecutive Vice President and Chief Legal OfficerExecutive Vice President and Chief of Cell and Genetic TherapiesExecutive Vice President and Chief Operating OfficerExecutive Vice President and Chief Patient OfficerExecutive Vice President and Chief Regulatory and Quality OfficerExecutive Vice President and Chief Scientific OfficerExecutive Vice President and Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical OfficerExecutive Vice President, Global Research and Chief Scientific OfficerExterior of Vertex headquarters in Boston, MAExterior of Vertex headquarters in Paddington, UKExterior of Vertex research site in Oxford, UKExterior of Vertex research site in San Diego, CAImagesInterior of Vertex headquarters in Boston, MALiving with beta thalassemiaLiving with sickle cell diseaseLiving with transfusion-dependent beta thalassemiaLiving with transfusion-dependent thalassemiaMother to three daughters living with sickle cell diseaseResearcher in Vertex Oxford labResearcher in Vertex San Diego labResearchers in Vertex Boston labResearchers in Vertex Oxford labResearchers in Vertex San Diego lab Jeffrey Leiden, M.D., Ph.D. Executive Chairman Download Date - Any -2021202220232024 Tags Chief Executive Officer and PresidentDownload LibraryEmployee working at Vertex Manufacturing Center (VMC), Boston, MAEmployee working at Vertex Manufacturing Center, Boston, MAEntrance of The Jeffrey Leiden Center for Cell and Genetic Therapies, Boston, MAExecutive ChairmanExecutive Vice President and Chief Financial OfficerExecutive Vice President and Chief Legal OfficerExecutive Vice President and Chief of Cell and Genetic TherapiesExecutive Vice President and Chief Operating OfficerExecutive Vice President and Chief Patient OfficerExecutive Vice President and Chief Regulatory and Quality OfficerExecutive Vice President and Chief Scientific OfficerExecutive Vice President and Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical OfficerExecutive Vice President, Global Research and Chief Scientific OfficerExterior of Vertex headquarters in Boston, MAExterior of Vertex headquarters in Paddington, UKExterior of Vertex research site in Oxford, UKExterior of Vertex research site in San Diego, CAImagesInterior of Vertex headquarters in Boston, MALiving with beta thalassemiaLiving with sickle cell diseaseLiving with transfusion-dependent beta thalassemiaLiving with transfusion-dependent thalassemiaMother to three daughters living with sickle cell diseaseResearcher in Vertex Oxford labResearcher in Vertex San Diego labResearchers in Vertex Boston labResearchers in Vertex Oxford labResearchers in Vertex San Diego lab Vertex International Headquarters Paddington – Lobby Download 915 KB Date - Any -2021202220232024 Tags Chief Executive Officer and PresidentDownload LibraryEmployee working at Vertex Manufacturing Center (VMC), Boston, MAEmployee working at Vertex Manufacturing Center, Boston, MAEntrance of The Jeffrey Leiden Center for Cell and Genetic Therapies, Boston, MAExecutive ChairmanExecutive Vice President and Chief Financial OfficerExecutive Vice President and Chief Legal OfficerExecutive Vice President and Chief of Cell and Genetic TherapiesExecutive Vice President and Chief Operating OfficerExecutive Vice President and Chief Patient OfficerExecutive Vice President and Chief Regulatory and Quality OfficerExecutive Vice President and Chief Scientific OfficerExecutive Vice President and Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical OfficerExecutive Vice President, Global Research and Chief Scientific OfficerExterior of Vertex headquarters in Boston, MAExterior of Vertex headquarters in Paddington, UKExterior of Vertex research site in Oxford, UKExterior of Vertex research site in San Diego, CAImagesInterior of Vertex headquarters in Boston, MALiving with beta thalassemiaLiving with sickle cell diseaseLiving with transfusion-dependent beta thalassemiaLiving with transfusion-dependent thalassemiaMother to three daughters living with sickle cell diseaseResearcher in Vertex Oxford labResearcher in Vertex San Diego labResearchers in Vertex Boston labResearchers in Vertex Oxford labResearchers in Vertex San Diego lab Vertex Logo with Tagline Download 2 MB | 2951 x 1952 Mediainfo@VRTX.com
Jan 10 2025 Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore Read More
Dec 23 2024 Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13 Read More
Dec 20 2024 Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis Read More
Dec 20 2024 Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non-F508del TRIKAFTA-Responsive Variants Read More
Dec 19 2024 Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy Read More
Dec 08 2024 Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the American Society of Hematology (ASH) Annual Meeting and Exposition and Provides Program Update Read More
